283 related articles for article (PubMed ID: 33099432)
1. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
Wong SW; Fogaren T
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
[TBL] [Abstract][Full Text] [Related]
2. Systemic Amyloidosis due to Monoclonal Immunoglobulins: Cardiac Involvement.
Saith SE; Maurer MS; Patel AR
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1055-1068. PubMed ID: 33099423
[TBL] [Abstract][Full Text] [Related]
3. Liver and Gastrointestinal Involvement.
Rosenzweig M; Comenzo RL
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1081-1090. PubMed ID: 33099425
[TBL] [Abstract][Full Text] [Related]
4. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
6. Supportive Care in AL Amyloidosis.
Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
[TBL] [Abstract][Full Text] [Related]
7. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
8. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
9. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Nervous System Involvement.
Thaisetthawatkul P; Dyck PJB
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1091-1098. PubMed ID: 33099426
[TBL] [Abstract][Full Text] [Related]
11. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
13. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
14. Kidney and liver involvement in monoclonal light chain disorders.
Pozzi C; Locatelli F
Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
16. Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.
Karam S; Leung N
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1069-1079. PubMed ID: 33099424
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
18. Systemic AL (light-chain) amyloidosis and the gastrointestinal tract.
Sattianayagam P; Gibbs S; Hawkins P; Gillmore J
Scand J Gastroenterol; 2009; 44(11):1384-5. PubMed ID: 19891590
[No Abstract] [Full Text] [Related]
19. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
Van Doren L; Lentzsch S
Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
[TBL] [Abstract][Full Text] [Related]
20. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response.
Palladini G; Milani P; Basset M; Russo F; Lavatelli F; Nuvolone M; Ferraro G; Bozzola M; Foli A; Perlini S; Merlini G
Amyloid; 2017 Mar; 24(sup1):54-55. PubMed ID: 28434293
[No Abstract] [Full Text] [Related]
[Next] [New Search]